Novartis has announced that the US Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS, BARDA) has awarded Novartis Vaccines a contract for up
She previously worked for Focus Diagnostics/Quest for over 20 years in a wide-ranging role encompassing sales and marketing, technical advisory and business development. Stephen Little, chief executive officer
Results of operations Consolidated net sales for Biomerica were $2,314,920 for the first six months of fiscal 2009 as compared to $2,367,599 for the same period in the
Bland also held various sales and management positions in cardiovascular disease with Kos Pharmaceuticals before the company was sold to Abbott. Bland received his B.S. and his M.B.A.
Under this agreement, Apitope has granted exclusive worldwide rights to Merck Serono to develop and commercialize Apitope’s product ATX-MS-1467. This peptide therapeutic has completed an initial clinical study
MacuCLEAR is developing MC 1101 for the treatment and prevention of the progression of age related macular degeneration (AMD). Mystic Pharmaceuticals said that it has developed a novel
The letter outlined questions that the FDA identified during its review of the new drug application (NDA) for over-the-counter (OTC) Zegerid. Santarus said that it is in regular
Under the terms of the option agreement, Cephalon will pay Ception a $100 million upfront option payment. Ception’s lead product is reslizumab. Reslizumab is a humanized monoclonal antibody
Xenazine is the first and only FDA-approved treatment specifically developed for any Huntington’s disease-related symptom, the company said. Paul Dreyer, president of S&R, said: “In recent months, the
In this role, Mr Lee will draw upon his 24 years of pharmaceutical sales and marketing experience to lead the prospective launch and commercialization of new products for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.